'Imiquimod should be used for treatment of [superficial basal cell carcinoma] only when surgery is medically less appropriate ... .' USA Food And Drug Administration, 'FDA Approval for Imiquimod', [1], current at 2011-Jan-1, accessed 2012-Oct-19
cancer.org
American Cancer Society, Guide To Cancer Drugs, >[2] (accessed 2014-Apr-28)
R.L Miller, J.F Gerster, M.L Owens, H.B Slade et M.a Tomai, « Review Article Imiquimod applied topically: A novel immune response modifier and new class of drug », International Journal of Immunopharmacology, vol. 21, no 1, , p. 1–14 (PMID10411278, DOI10.1016/s0192-0561(98)00068-x)
harvard.edu
ui.adsabs.harvard.edu
Anne Walter, Matthias Schäfer, Virginia Cecconi, Claudia Matter, Mirjana Urosevic-Maiwald, Benedetta Belloni, Nicola Schönewolf, Reinhard Dummer, Wilhelm Bloch, Sabine Werner, Hans-Dietmar Beer, Alexander Knuth et Maries Van Den Broek, « Aldara activates TLR7-independent immune defence », Nature Communications, vol. 4, , p. 1560 (PMID23463003, DOI10.1038/ncomms2566, Bibcode2013NatCo...4E1560W)
R.L Miller, J.F Gerster, M.L Owens, H.B Slade et M.a Tomai, « Review Article Imiquimod applied topically: A novel immune response modifier and new class of drug », International Journal of Immunopharmacology, vol. 21, no 1, , p. 1–14 (PMID10411278, DOI10.1016/s0192-0561(98)00068-x)